ANV-AH5 administration following cisplatin resulted in the best tumor control, prolonged survival of mice, and the generation of the strongest systemic and tumor-infiltrating AH5-specific CD8+ T-cell response compared to those with other treatment regimens [29]. Here, CD8A is linked to neoplasm.